All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Results from an analysis of the incidences of cutaneous infections in patients with psoriasis who received systemic treatment were published in The Journal of Dermatology by Higashi et al.1 This study included 878 patients from the Western Japan Psoriasis Registry.1 |
Key learnings: |
In patients with psoriasis who underwent systemic biologic treatment, cutaneous bacterial infections occurred in 12/878 patients, with cellulitis being the most common (67%); treatment with TNF-α inhibitors (odds ratio [OR], 9.917; 95% confidence interval [CI], 2.069–47.572; p = 0.0041) and IL-17 inhibitors (OR, 10.798; 95% CI, 2.35–49.616; p = 0.0022), were associated with an increased risk of cutaneous bacterial infections. |
Cutaneous viral infections occurred in 11/878 patients, predominantly herpes zoster (82%); a history of otitis media (OR, 4.499; 95% CI, 1.281–15.804; p = 0.019) and treatment with oral therapies (OR, 3.804; 95% CI, 1.141–12.679; p = 0.0296) were associated with a higher incidence of cutaneous viral infections. |
Cutaneous fungal infections were observed in 45/878 patients, most commonly trichophytosis (73%); receiving IL-17 inhibitors (OR, 3.291; 95% CI, 1.744–6.209; p = 0.0002) and older age (OR, 1.04; 95% CI, 1.007–1.073; p = 0.0003) were associated with a higher prevalence of cutaneous fungal infections. |
These findings emphasize the need for dermatologists to monitor for signs of cutaneous infections in patients with psoriasis receiving systemic therapy and to provide appropriate precautions. |
Your opinion matters
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox